FIELD: pharmaceuticals.
SUBSTANCE: present invention relates to the use of an oral pharmaceutical composition with prolonged release containing R-(+)-N-propargyl-1-aminoindane (rasagiline) or a pharmaceutically acceptable salt thereof as an active agent for treating Parkinson's disease, wherein the active agent dose is 0.2 to 2.0 mg a day, and said composition has dissolution characteristics in Apparatus 1 (basket) according to United States Pharmacopoeia (USP) at 50–150 rpm at a pH value of up to 7.4, at 37 °C, wherein 30–70 % of said active agent is released during the first six hours. Present invention also relates to a method of treating Parkinson's disease in an individual in need thereof.
EFFECT: technical result of the present invention is preparing a pharmaceutical composition prepared in a form for prolonged release of the active compound, suitable for treating neurodegenerative diseases, particularly Parkinson's disease, as well as injuries of the nervous system.
12 cl, 9 dwg, 17 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RASAGILINE COMPOSITIONS OF PROLONGED RELEASE AND USE THEREOF | 2011 |
|
RU2607595C2 |
| PARKINSON'S DISEASE THERAPY WITH APPLICATION OF COMBINATION WITH FIXED DOSES | 2013 |
|
RU2642962C9 |
| PARKINSON'S DISEASE THERAPY USING COMBINATION WITH FIXED DOSAGES | 2013 |
|
RU2771522C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| COMPOSITIONS OF RASAGILINE WITH IMPROVED HOMOGENEITY OF CONTENT | 2006 |
|
RU2404746C2 |
| USE OF RASAGILINE FOR TREATMENT OF OLFACTORY DYSFUNCTION | 2011 |
|
RU2587330C2 |
| COMPOSITIONS OF L-ORNITHINE PHENYL ACETATE | 2016 |
|
RU2755904C2 |
| METHOD OF TREATMENT OF CARDIOVASCULAR DISEASES | 1999 |
|
RU2207856C2 |
| METHODS OF PARKINSON'S DISEASE TREATMENT | 2004 |
|
RU2342929C2 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
